Hexamethylmelamine formulation exhibiting reduced neurotoxicity
US5004593A · kind A · utility
7Cited by
2References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 17, 1989 |
| Grant date | Apr 2, 1991 |
| Priority date | — |
| Expiry date | Apr 17, 2009 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method is provided for reducing the side effects of chemotherapy with hexamethylmelamine (HMM) comprising intravelously administering a stabilized solution of HMM in an aqueous lipid dispersion, so that the central nervous system toxicity associated with oral HMM administration is reduced or eliminated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.